Coloplast A/S
Coloplast A/S
- ISIN: DK0010309657
- Land: .
Nachricht vom 26.04.2012 | 13:16
Coloplast raises earnings expectations
Coloplast A/S
26.04.2012 13:16
---------------------------------------------------------------------------
Revenue was up 7% to DKK 5,346m in the first half of the financial year
2011/2012 and the EBIT margin was 27% against 24% during the same period last
year.
'I'm very pleased. We continue to grow more than the market and have delivered
a solid result which means we can raise our earnings expectations for this
financial year,' says CEO Lars Rasmussen.
The revenue growth expectations for the financial year 2011/2012 continue to be
about 6% at constant exchange rates and about 8% in DKK based on current
exchange rates. The EBIT margin is raised from about 27% to about 28% at
constant exchange rates and from about 28% to around 29% in DKK based on
current exchange rates.
Ready to invest in growth
Coloplast's Board of Directors today approved an updated strategy for the next
3-5 years which aims to accelerate growth.
'The combination of a strong portfolio of new products and a stronger, more
professional sales force means that we now have the foundation to accelerate
growth.'
'Furthermore, we have over the past four years improved the company's
profitability significantly which means that we are now ready to invest up to 1
billion Danish kroner in growth during the next five years while maintaining
earnings in line with the best in the market, 'says Lars Rasmussen.
The future investments should maintain and strengthen Coloplast's position as
market leader in Europe, strengthening growth in the developed markets outside
Europe (U.S., Canada, Japan and Australia) as well as providing greater
expansion into new markets including China.
Coloplast today announced a new sales organisation, which supports the updated
strategy. For more details go to H1 Announcement
Coloplast's long-term financial ambition is to outgrow the market while
achieving earnings margins that are in line with the best performing med-tech
companies.
www.coloplast.com
PRESS
Ulla Lundhus
Media Relations Manager
+45 4911 1929
dkul@coloplast.com
INVESTOR RELATIONS
Ian Christensen
Vice President, Investor Relations
+45 4911 1301
dkisec@coloplast.com
News Source: NASDAQ OMX
26.04.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Coloplast A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010309657
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Interaktiv
Weitere News
Anleihe im Fokus
Die DF-Anleihe 7,875%
Mit der DF Forfait AG vom wachsenden Welthandel profitieren
- Zeichnungsfrist: 21.05. bis 24.05.2013
- Laufzeit: 7 Jahre
- Kupon: 7,875% p.a.
- Volumen: bis zu 30 Mio. Euro
- ISIN: DE000A1R1CC4
Anleihe im Fokus
7,75% p.a. - Rendite aus Familienhand
– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs
GBC-Fokusbox
HELMA Eigenheimbau AG: Kaufen
Die HELMA Eigenheimbau AG präsentierte für das Geschäftsjahr 2012 Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen fairen Wert je Aktie von 22,75 € ermittelt. Ausgehend vom erwarteten 2013er-EPS von 1,64 € entspricht dies einem KGV von 8,4. Das Kurspotenzial beläuft sich auf nahezu 65%.
Der AKTIONÄR News

19. Mai 14:30 Investieren wie Warren Buffett: Verdienen Sie 4.809 Euro in den ...
19. Mai 10:30 Lufthansa und die Angst vor dem Streik
19. Mai 09:00 ThyssenKrupp: Es bleibt spannend
19. Mai 08:00 Die Prognosen der Profis
19. Mai 07:30 Talanx: Analysten heben den Daumen
News im Fokus
Fresenius Medical Care AG & Co. KGaA: Bekanntmachung nach Art. 4 Abs. 2 der Verordnung (EG) Nr. 2273/2003
17. Mai 2013, 17:35
Aktuelle Research-Studie
Original-Research: Plan Optik AG (von GBC AG): Kaufen Plan Optik AG
17. Mai 2013
